STOCK TITAN

Ensysce Biosciences Inc - ENSC STOCK NEWS

Welcome to our dedicated news page for Ensysce Biosciences (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ensysce Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ensysce Biosciences's position in the market.

Rhea-AI Summary
Ensysce Biosciences receives IRB approval for PF614 study, progressing towards Phase 3 evaluation. PF614 shows bioequivalence to OxyContin and limited desirability for recreational drug use. Study to confirm time of onset for pain relief. Safety data accumulation for regulatory submissions. Potential game changer for severe pain treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ:ENSC) has engaged Alacrita Consulting to explore partnering and licensing opportunities for its TAPP and MPAR® platforms and products. The goal is to aid expansion of the use of TAAP and MPAR® technologies and to rapidly develop PF614 and PF614-MPAR opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ:ENSC) has announced the pricing of a public offering of its common stock and warrants. The offering includes 1,800,876 shares of common stock, Series A-1 warrants to purchase up to 1,800,876 shares of common stock, and Series A-2 warrants to purchase 1,800,876 shares of common stock. The combined public offering price is $3.887 per share. The gross proceeds from the offering are expected to be approximately $7 million. The closing of the offering is expected on May 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.11%
Tags
Rhea-AI Summary
Ensysce Biosciences completes clinical study for PF614-MPAR, a pain medication with overdose protection. Study shows successful reduction of opioid delivery when multiple doses are consumed simultaneously. Potential game-changer for severe pain treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.48%
Tags
none
Ensysce Biosciences Inc

Nasdaq:ENSC

ENSC Rankings

ENSC Stock Data

5.46M
7.14M
5.55%
2.32%
0.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
La Jolla

About ENSC

ensysce biosciences, san diego, ca, is an integrated drug delivery company for both small and large molecules. to overcome the major problem of non-medical use of opioid products, ensysce is using its prodrug technology to improve abuse deterrent properties. the tap bio-md™ abuse deterrent and mpar™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route. this abuse is the fastest growing drug problem in the u.s. and it leads to billions in healthcare costs annually. for additional information about ensysce biosciences please visit www.ensysce.com.